PREVIEW: Eli Lilly and Co (LLY) earnings due 03/Feb at 11:25GMT/06:25EST

Eli Lilly and Co (LLY) Q4 2021 (USD): EPS (exp. 2.46/2.93 GAAP), Revenue (exp. 7.73bln)

KEY PHARMA SALES:

• Trulicity: (exp. 1.80bln)
• Humalog: (exp. 662mln)
• Bamlanivimab/LY-COV555: (exp. 648mln)
• Taltz/Ixekizumab: (exp. 640mln)
• Alimta: (exp. 496mln)

DIVIDEND:

• Qtrly Dividend: (exp. 0.85)
• FY Dividend: (exp. 3.35)

EPS GUIDANCE:

• Q1 2021 EPS View: (exp. 2.10)
• FY 2021 EPS View: (exp. 8.52)

REVENUE GUIDANCE:

• Q1 2022 Revenue View: (exp. 6.88bln)
• FY 2022 Revenue View: (exp. 28.04bln)

INDEX WEIGHT:

• 0.6% SPX weight
• Sector/Industry: Health Care/Pharmaceuticals

BROKER RATING:

• Avg Rating: 'Buy'
• Avg Price Target: USD 285.42
• Price Target Changes (last 30 days): 3 upward vs 3 downward